Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Opioid Abuse-Deterrence: Immediate Release Formulation Is Chance For US FDA To Reassess Goal Posts

Executive Summary

Inspirion's RoxyBond would be first immediate-release oxycodone with abuse deterrent properties, and it seems backed by solid data, but first it needs to make it past two advisory committee all too familiar with the law of unintended consequences.

Advertisement

Related Content

RoxyBond Clears US FDA With Abuse-Deterrent Properties, But No REMS Yet
Abuse-Deterrent Opioids: Postmarketing Data Eyed As Development ‘Anchor’
RoxyBond Gets US Advisory Panel OK For Abuse-Deterrent Claim Despite Excipient Concerns
Egalet's Bid For Arymo ER Intranasal Abuse-Deterrence Claim Blocked By MorphaBond Exclusivity
US FDA guides on abuse-deterrent opioids; generics direction pending

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS120367

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel